SCHEDULE 13G/A: BlackRock Maintains Significant 7.2% Stake in Denali Therapeutics Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a continued 7.2% beneficial ownership stake in Denali Therapeutics Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed Amendment No. 5 to Schedule 13G concerning its beneficial ownership in Denali Therapeutics Inc. Common Stock.
• As of March 31, 2025, BlackRock beneficially owned 10,490,610 shares of Denali Therapeutics Inc.
• This ownership represents 7.2% of the total outstanding common stock of Denali Therapeutics Inc.
• BlackRock holds sole voting power over 10,304,269 shares and sole dispositive power over 10,490,610 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• The filing was made by BlackRock, Inc. as a parent holding company, with various BlackRock subsidiaries identified as entities that may beneficially own shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is purely factual about ownership, but the continued significant stake by a major institutional investor like BlackRock can be interpreted as a positive signal of confidence in Denali Therapeutics.

Positives

• BlackRock, a prominent global asset manager, maintaining a significant 7.2% stake in Denali Therapeutics Inc. may signal continued institutional confidence in the company.
• The acquisition and holding of shares are stated to be in the ordinary course of business, indicating a passive investment rather than an activist stance that could introduce uncertainty.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Denali Therapeutics Inc.'s future outlook or financial performance.

Management Comments

• BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a standard disclosure by a major institutional investor in a biotechnology company. Large asset managers like BlackRock frequently take significant passive stakes in companies across various sectors, including biotech, as part of their diversified investment strategies. This indicates continued institutional interest in Denali Therapeutics within the broader pharmaceutical and biotechnology landscape.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports an ownership stake and does not provide performance metrics or operational results for direct comparison to industry standards or specific comparable companies. It adheres to the regulatory requirements for disclosing significant passive ownership by institutional investors.

Stakeholder Impact

• Shareholders of Denali Therapeutics Inc. may perceive BlackRock's continued significant ownership as a positive indicator of institutional support and stability.
• No direct impact on employees, customers, suppliers, or creditors of Denali Therapeutics Inc. is indicated by this ownership disclosure.

Next Steps

• BlackRock, Inc. will continue to file amendments to its Schedule 13G if there are material changes to its beneficial ownership stake in Denali Therapeutics Inc.

Key Dates

Keywords

Denali Therapeutics Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals